Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU1-63P is classified as a pseudogene of the U1 small nuclear RNA family, located in the human genome at cytogenetic region 4:67429591-67429754[3][4][5]. Pseudogenes are genomic DNA sequences similar to normal genes but are non-functional; they generally do not produce functional RNA or protein products. In the case of RNU1-63P, there is no evidence supporting its expression as a functional gene or involvement in known biological processes, disease mechanisms, or as a pharmacological target[1][3][5]. While canonical U1 snRNA genes (e.g., RNU1-1) play key roles in pre-mRNA splicing as core components of the spliceosome, RNU1-63P itself is not known to encode a functional RNA and is not considered a therapeutic target or biomarker[1][2][3]. No drugs or modulators are reported to interact specifically with RNU1-63P, and it has no recognized role in clinical diagnostics or therapeutics[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U1 small nuclear 63, pseudogene (RNU1-63P).